Skip to main content
. 2024 Feb 12;130(8):1316–1323. doi: 10.1038/s41416-023-02569-4

Fig. 1. BM-iPFS.

Fig. 1

In our analyses, intracranial progression-free survival from BM (brain metastasis) resection (BM-iPFS) was improved in case of low TMB (Tumor Mutation Burden) (<5.02 Mut/Mb) (a) and absence of HER2 amplification (HER2+) (b) on BM; on the contrary, no correlation was observed with KRAS status (c) or TILs (Tumor Infiltrating Lymphocytes) on BM (d).